At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 31 enrolled
Drug / intervention
IXAZOMIBdrug
Likely dose
IXAZOMIB 0.125 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Dose-Escalation, Phase 1 Study of IXAZOMIB (MLN9708), A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma
In Brief
A Phase 1 clinical trial evaluating IXAZOMIB for Lymphoma. Completed, enrolled 31 participants across 7 sites in 2 countries.
Detailed Summary
This study is an open-label, multicenter, phase 1, dose-escalation study of IXAZOMIB in adult patients with lymphoma. This study will be the first to administer IXAZOMIB to patients with lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesCanada, United States
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartAug 2009
Primary CompletionOct 2014
TodayJul 2026
First PostedMay 6, 2009
Enrollment StartAug 1, 2009
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 17.2 years ago
Interventions
IXAZOMIBdrug
Patients will be administered IXAZOMIB by IV on Days 1, 8, and 15 of a 28-day cycle. The first stage of the study will be initiated at a starting dose of 0.125 mg/m2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.